mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

BACKGROUND: Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models. METHODS: Human and murine HCC cells, endothelial c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Autores principales: Scheller, T, Hellerbrand, C, Moser, C, Schmidt, K, Kroemer, A, Brunner, S M, Schlitt, H J, Geissler, E K, Lang, S A
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453944/
https://ncbi.nlm.nih.gov/pubmed/25688743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.638
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares